Combo Products User Fee Final Guidance Reflects Industry Comments
This article was originally published in The Gray Sheet
Executive Summary
A FDL-1final guidance released April 21 by FDA's Office of Combination Products assures industry stakeholders that user fee waivers are attainable if a firm decides to submit two applications instead of one
You may also be interested in...
Concept Papers Seek Industry Input On Combo Product Issues
FDA seeks feedback on two concept papers offering preliminary thoughts on adverse event reporting and on the number of applications needed for a combination product
Concept Papers Seek Industry Input On Combo Product Issues
FDA seeks feedback on two concept papers offering preliminary thoughts on adverse event reporting and on the number of applications needed for a combination product
Combo Products User Fees: Industry Comments On FDA Guidance, Eyes Future
Legislating separate user fees for combination products could be debated when device or drug user fee programs come up for reauthorization